Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
The efficacy and safety of LixiLan, a tratable fixed-ratio combination of insulin glargine plus lutein in Type 2 diabetes inadequately controlled with basal insulin and metformin: the LixiLan-L randomized study.